BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34399152)

  • 1. Ligand-based design approach of potential Bcl-2 inhibitors for cancer chemotherapy.
    Arakal NG; Sharma V; Kumar A; Kavya B; Devadath NG; Kumar SB; Murthy KT; Murahari M
    Comput Methods Programs Biomed; 2021 Sep; 209():106347. PubMed ID: 34399152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy.
    Krishna S; Kumar SB; Murthy TPK; Murahari M
    Comput Biol Med; 2021 Jul; 134():104455. PubMed ID: 33962088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
    Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
    Front Chem; 2020; 8():167. PubMed ID: 32328476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics.
    Parate S; Kumar V; Danishuddin ; Hong JC; Lee KW
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34156395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
    Jana S; Singh SK
    J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
    Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
    J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y; Zhou L; Hu Y; Bao Y
    J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HER2 inhibitors from curcumin derivatives using combination of
    Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
    J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-based pharmacophore modeling and QSAR approach to identify potential dengue protease inhibitors.
    Poola AA; Prabhu PS; Murthy TPK; Murahari M; Krishna S; Samantaray M; Ramaswamy A
    Front Mol Biosci; 2023; 10():1106128. PubMed ID: 36911525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK; Jeyaraman J
    J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
    Dev S; Dhaneshwar SR; Mathew B
    Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
    Zaka M; Abbasi BH; Durdagi S
    J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
    Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
    J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
    Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
    J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors.
    Shaikh GM; Murahari M; Thakur S; Kumar MS; Yc M
    J Mol Graph Model; 2022 May; 112():108114. PubMed ID: 34979367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.